This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aegerion Target of SEC Probe Related to Drug Sales Practices

01/13/15 - 09:12 AM EST

Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.

READ FULL POST

Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival

01/12/15 - 07:07 AM EST

Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.

READ FULL POST

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

01/09/15 - 02:56 PM EST

Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.

READ FULL POST

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients

01/05/15 - 10:52 AM EST

Final results from a mid-stage study of Brainstorm's NurOwn therapy show a slowing of disease progression in some ALS patients.

READ FULL POST

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

12/19/14 - 04:16 PM EST

U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.

READ FULL POST

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

12/19/14 - 08:25 AM EST

European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

READ FULL POST

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

12/16/14 - 11:20 AM EST

One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.

READ FULL POST

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

12/15/14 - 09:23 AM EST

Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.

READ FULL POST

Array Biopharma Regains Rights to Cancer Drug From Novartis

12/03/14 - 04:01 PM EST

The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.

READ FULL POST

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia

12/03/14 - 01:31 PM EST

Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.

READ FULL POST

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs